Search for contacts, projects,
courses and publications

Francesco Bertoni


Francesco Bertoni, born in Rome (Italy), 1969, married, two daughters. Medical Doctor, post-graduated in Oncology, fully devoted to cancer research with two research aims: 1) Development of novel drugs for patients affected by lymphomas, 2) Identification of genetic or epigenetic alterations in lymphomas as tools to predict the outcome and the response to therapies or as new therapeutic targets. Research background comprises working experiences at Bone Marrow Transplant Laboratory of the Oncology Institute of Southern Switzerland (IOSI), at the Molecular Hematology Unit of the Institute of Child Health (London, UK), at the Molecular Pharmacology Unit of the Department of Oncology at the Mario Negri Institute for Pharmacological Research (Milan, Italy), and at the Department of Experimental Hematology at the Barts And The London (London, UK). Since April 2003, he is the principal investigator for the lymphoma lab projects and responsible for the functional genomics of the Laboratory of Experimental Oncology of the IOSI, and since April 2007, he is also the laboratory vice-director. Bertoni is the author or co-author of over 180 original papers, over 40 editorial or invited reviews, over 20 book sections, one edited book and several abstracts at national and international meetings. Since January 2009 he is the Editor-in-Chief of Hematological Oncology. Bertoni has supervised several Master and PhD students. 


On-going projects

-      An integrated approach to identify the mechanism of resistance to copanlisib and venetoclax in marginal zone lymphoma

-      Transcriptome analysis to improve the outcome prediction and to identify novel therapeutics targets in follicular lymphoma patients

-      Genetic screening of enhancer RNAs to understand their causative biological role in refractory diffuse large B cell lymphoma

-      Development of a microfluidic platform for real-time detection of SARS-CoV-2 virus based on multifunctional silica membrane biosensors

-      Characterization of specific enhancer RNAs involved in ibrutinib resistance mechanism in marginal zone lymphoma

-      Ultra-conserved long non-coding RNAs in B-cell lymphoma

-      Finding a way to by-pass the resistance to PI3K inhibitors in marginal zone lymphomas 

-      An implantable device to tailor treatment in patients with lymphoma

-      CA18238 - European transdisciplinary networking platform for marine biotechnology

-      Targeted agents in splenic marginal zone lymphoma: mechanisms of resistance and new combinations

-      An international phase III multicenter, randomized study with lenalidomide maintenance versus observation after intensified induction regimen containing rituximab followed by high dose chemotherapy and autologous stem cell transplantation as first line treatment in adult patients with advanced mantle cell lymphoma: Identification of DNA and methylation changes associated with the clinical outcome

-      Development of novel anti-lymphoma agents